Gause

Researchers are evaluating YL205, a drug given by intravenous infusion, in patients with advanced solid tumors. This multicenter, open-label phase III study in China aims to assess the safety, tolerability, pharmacokinetics how the drug moves through the body, and preliminary effectiveness of YL205. Eligible patients have advanced solid tumors that overexpress Napi2B and include cancers such as ovarian, non-squamous non-small cell lung, renal cell, and endometrial cancer. Participants receive YL205 as a lyophilized powder reconstituted for intravenous infusion at a dose of 160 mg per vial. Treatment is given once every three weeks in cycles, with dose levels adjusted during different study phases dose escalation phase Ia, dose expansion phase Ib, and cohort expansion phase II. The study evaluates at least two dose levels and the recommended phase 2 dose RP2D. Throughout approximately 36 months, participants are closely monitored for dose-limiting toxicities, treatment-emergent adverse events, and serious adverse events. Researchers assess tumor response using RECIST v1.1 criteria, including overall response rate, disease control rate, duration and depth of response, progression-free survival, and overall survival. Pharmacokinetic parameters like AUC, Cmax, and half-life are also measured. Patients undergo tumor sampling and radiological evaluations to track treatment effects and safety.

Researchers are evaluating the safety, tolerability, pharmacokinetics, and early activity of a drug called RO7656594 in men with advanced or metastatic prostate cancer. This phase 1 study aims to find the recommended doses and treatment schedules for RO7656594 for future research. Participants have prostate adenocarcinoma without small-cell or neuroendocrine features and have received prior hormone and chemotherapy treatments. Participants will receive RO7656594 orally at specified doses on certain days within 28-day cycles. The dose will be gradually increased in groups of participants until a specific threshold is reached, after which participants will receive doses at or below the maximum tolerated or administered dose. The study includes dose escalation and expansion stages to assess safety and activity. During the study, participants will be closely monitored for side effects and dose-limiting toxicities from the first day of treatment through up to 28 days after the final dose, potentially lasting about 24 months. Blood samples will be taken at multiple points to measure drug levels, and prostate-specific antigen PSA responses will be evaluated. This monitoring helps researchers understand how the drug behaves in the body and its potential effects on the cancer over time.